Then, sequentially add 0.5 mL of catalyst I (0.50 g/100 mL triethylamine in chloroform solution) and 0.5 mL of catalyst II (0.50 g/100 mL n-butyl chloroformate in chloroform solution)
Archives of Pharmacal Research , 42 (3), 252262
1:2500, Abcam, Cambridge, UK), Drp-1 (1:2000, Novus Biotechnology, Littleton, CO, USA), Opa-1 (1:2000, Novus Biotechnology, Littleton, CO, USA), LC3A/B (1:2000, Cell Signaling Technology, Danvers, MA, USA), Tom-20 (1:2000, Santa Cruz Biotechnology, Dallas, TX, USA) and MnSOD (1:2000, Millipore, Billerica, MA, USA), Pink-1 (1:1000, BioVision Incorporated, Milpitas, CA, USA), Fis-1 (1:500, Santa Cruz Biotechnology, Dallas, TX, USA) and Parkin (1:500, Cell Signaling Technology, Danvers, MA, USA) for overnight
Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs
Patients see a smaller waistline, less deep abdominal fat, and preserved muscle